Capital Investment Services of America Inc. Acquires 949 Shares of Veeva Systems Inc. $VEEV

Capital Investment Services of America Inc. lifted its holdings in Veeva Systems Inc. (NYSE:VEEV) by 1.2% in the 2nd quarter, Holdings Channel.com reports. The firm owned 80,686 shares of the technology company’s stock after buying an additional 949 shares during the quarter. Veeva Systems makes up about 2.1% of Capital Investment Services of America Inc.’s holdings, making the stock its 24th largest holding. Capital Investment Services of America Inc.’s holdings in Veeva Systems were worth $23,236,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Veeva Systems by 2.2% in the first quarter. Vanguard Group Inc. now owns 14,760,566 shares of the technology company’s stock valued at $3,418,990,000 after buying an additional 315,421 shares during the period. Alliancebernstein L.P. increased its holdings in Veeva Systems by 10.7% during the first quarter. Alliancebernstein L.P. now owns 5,499,651 shares of the technology company’s stock worth $1,273,884,000 after buying an additional 532,269 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Veeva Systems by 0.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 5,203,867 shares of the technology company’s stock valued at $1,205,372,000 after purchasing an additional 34,169 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Veeva Systems by 20.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock valued at $924,754,000 after buying an additional 689,700 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Veeva Systems by 7.5% in the 1st quarter. JPMorgan Chase & Co. now owns 3,230,758 shares of the technology company’s stock valued at $748,341,000 after acquiring an additional 225,125 shares during the period. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Veeva Systems news, SVP Jonathan Faddis sold 720 shares of the firm’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $298.12, for a total value of $214,646.40. Following the transaction, the senior vice president directly owned 7,868 shares of the company’s stock, valued at $2,345,608.16. This trade represents a 8.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the completion of the transaction, the insider owned 25,325 shares of the company’s stock, valued at $7,765,151.50. The trade was a 19.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,665 shares of company stock worth $7,438,000 over the last ninety days. Corporate insiders own 10.30% of the company’s stock.

Veeva Systems Trading Down 0.1%

Shares of VEEV stock opened at $289.50 on Thursday. The stock has a 50 day simple moving average of $284.11 and a 200 day simple moving average of $268.13. Veeva Systems Inc. has a 1 year low of $201.54 and a 1 year high of $310.50. The stock has a market cap of $47.45 billion, a P/E ratio of 59.45, a price-to-earnings-growth ratio of 2.24 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last released its earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. The company had revenue of $789.08 million for the quarter, compared to the consensus estimate of $768.49 million. During the same quarter in the previous year, the company posted $1.62 earnings per share. The business’s revenue was up 16.7% compared to the same quarter last year. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Analysts forecast that Veeva Systems Inc. will post 4.35 EPS for the current year.

Wall Street Analyst Weigh In

VEEV has been the subject of a number of research reports. Needham & Company LLC restated a “buy” rating and set a $355.00 target price on shares of Veeva Systems in a research note on Friday, October 17th. William Blair restated an “outperform” rating on shares of Veeva Systems in a report on Friday, October 17th. KeyCorp upped their target price on Veeva Systems from $285.00 to $325.00 and gave the company an “overweight” rating in a research report on Monday, July 14th. UBS Group lifted their price target on Veeva Systems from $285.00 to $310.00 and gave the stock a “neutral” rating in a report on Thursday, August 28th. Finally, Truist Financial upped their price objective on Veeva Systems from $268.00 to $275.00 and gave the company a “hold” rating in a report on Thursday, August 28th. Seventeen investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Veeva Systems currently has a consensus rating of “Moderate Buy” and an average price target of $307.58.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.